Chidamide combined with linperlisib in treatment of recurrent angioimmunoblastic T-cell lymphoma: report of 1 case and review of literature
10.3760/cma.j.cn115356-20231129-00088
- VernacularTitle:西达本胺联合林普利塞治疗复发性血管免疫母细胞性T细胞淋巴瘤1例并文献复习
- Author:
Yuanbin SONG
1
;
Jingxia XU
;
Yun WANG
;
Yang LIANG
;
Bingyi WU
Author Information
1. 中山大学肿瘤防治中心，广州 510555
- Keywords:
Immunoblastic lymphadenopathy;
Recurrence;
Histone deacetylase inhibitors;
Phosphatidylinositol-3-kinases
- From:
Journal of Leukemia & Lymphoma
2024;33(10):622-625
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effects of chidamide combined with linperlisib in treatment of recurrent angioimmunoblastic T-cell lymphoma (AITL) after autologous stem cell transplantation (ASCT).Methods:The clinical data of 1 patient with recurrent AITL receiving treatment of chidamide combined with linperlisib after ASCT in Sun Yat-Sen University Cancer Center in March, 2021 were retrospectively analyzed, and the related literatures were reviewed.Results:The 55- year-old male patient was presented with fatigue, night sweats and emaciation. According to the results of pathology, immunohistochemistry and imaging after admission, this patient was diagnosed as AITL. After treatment with venbutuximab + CDP (cyclophosphamide + doxorubicin + prednisone) regimen, the patient achieved complete remission, and then ASCT was performed. After the transplatation, programmed death receptor 1 inhibitor was maintained for 4 courses of treatment. It recurred 16 months after ASCT, and the patient achieved partial remission after 1 course of chidamide combined with linperlisib, and achieved complete remission after 2 courses of treatment. Later, recheck of hepatitis B virus showed a quantitative increase after the self withdrawal of anti hepatitis B drugs, and then the primary treatment was suspended. The last follow-up time was March, 2024, and recheck results of whole body enhanced magnetic resonance imaging indicated recurrence.Conclusions:The combination of chidamide and linperlisib is effective and safe in treatment of recurrent ATIL after ASCT.
